Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL253525 | 1.00 | LPL (0.45) | LPLLIPGROCK1CA1CA2 | |
| SCHEMBL1328329 | 0.88 | LPL (0.45) | LPLLIPGROCK1CA1CA2 | |
| SCHEMBL16290518 | 0.88 | LPL (0.45) | LPLLIPGROCK1CA1CA2 | |
| SCHEMBL2412157 | 0.85 | LPL (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL2408634 | 0.84 | CSF1R (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL20448945 | 0.84 | CSF1R (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL26927507 | 0.84 | LPL (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL365686 | 0.84 | AAK1 (0.45) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL142144 | 0.83 | LPL (0.49) | LPLLIPGROCK1CA1CA2 | |
| SCHEMBL130052 | 0.82 | LPL (0.40) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541809-B1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2025-06-25 | — | — | EP | disclosed |
| US-20240376073-A1 | QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-14 | — | — | US | disclosed |
| CN-115667264-A | Novel imidazo-pyrazine derivatives | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220396565-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | disclosed |
| CN-109963848-B | Substituted N- (3-fluoropropyl) -pyrrolidine compounds, preparation thereof and therapeutic use thereof | 赛诺菲 | 2022-07-05 | — | — | CN | disclosed |
| CN-108689924-B | 4-amino-6- (4-substituted phenyl) -pyridine-2-carboxylic acid esters and their use as herbicides | 美国陶氏益农公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396565-A1 | NOVEL HETEROCYCLIC COMPOUNDS | MRPL21, F12, MRPS34 | LPL 3989/4885LIPG 4596/4885ROCK1 3888/4885 |
| US-20240376073-A1 | QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CFTR, HRH1, HRH4 | LPL 4624/4885LIPG 4835/4885ROCK1 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.